For Professionals - Boneindex
For Professionals

For Healthcare Professionals – About the Bindex® Scan

Clinical Need

Osteoporosis is a significantly underdiagnosed condition. Globally, an estimated 200 million people live with osteoporosis, yet only about 25% have been diagnosed.

The goal of early diagnosis is to initiate treatment before the first fracture, improving patient outcomes and reducing long-term healthcare costs. Today, diagnosis relies heavily on dual-energy X-ray absorptiometry (DXA) scans—expensive, referral-based, and often limited to specialist settings.

The Bindex® Solution

Bindex® is a portable, radiation-free pulse-echo ultrasound device that measures cortical bone thickness at the tibia. It combines this with patient factors (age, height, weight) to calculate a Density Index—a proxy for proximal femur BMD as measured by DXA (the gold standard).

Key Features

  • Portable: Ideal for point-of-care use in primary care, pharmacy, and specialist clinics
  • Fast: Takes less than 30 seconds per scan
  • Radiation-free: No special facilities required
  • Immediate Results: Supports real-time decision-making

Scalable: Suitable for broad population screening and fracture risk triage

Clinical Validation

  • Reviewed by NICE (Medtech Innovation Briefing MIB106, 2017) as a device for investigating suspected osteoporosis
  • Validated in multiple clinical studies against DXA with 90% sensitivity and specificity
  • CE-marked, MHRA-registered, and FDA-cleared

Evidence Base

  • Over 4 million scans performed globally
  • 8+ peer-reviewed clinical studies across Europe and the US
  • High negative predictive value, especially for ruling out osteoporosis
  • Proven cost-effectiveness, saving €76-€121 per patient in healthcare system models

Integration Into Clinical Pathways

Treatment Initiation
Patients in the Red Zone (high risk) can begin osteoporosis treatment without a confirmatory DXA scan – particularly if additional risk factors are present. Peripheral BMD results in these cases offer high predictive value for osteoporosis diagnosis【1,2】.

Additional Assessment
While DXA may not be necessary for high-risk patients, a baseline scan can still be useful for follow-up. Clinical judgment remains essential – consider patient age, fracture history, and secondary causes.

Ongoing Management
Patients started on treatment should be monitored over time. Follow-up with Bindex® or DXA can help assess therapeutic response and guide treatment adjustments.

Bindex® is designed for use in a range of clinical settings, including:

  • Primary care and GP practices
  • Fracture liaison services (FLS)
  • Menopause and endocrinology clinics
  • Pre-operative orthopedic screening
  • Preventive and longevity medicine
  • Pharmacy-based health checks

Resources

References

  1. National Osteoporosis Society. Practical Guide to the Use of Peripheral X-ray Absorptiometry in the Management of Osteoporosis.

International Society for Clinical Densitometry (ISCD). 2019 Position Development Conference on Osteoporosis and Bone Densitometry.